Indication:

Hypolip ^® is indicated as an adjunct to diet for reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in patients with-
• Primary hypercholesterolemia (heterozygous familial and non-familial hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb)
• Elevated serum TG levels (Fredrickson type IV)
• Primary dysbetalipoproteinemia (Fredrickson type III) who do not respond adequately to diet.
• Homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are unavailable.

Dosage & Administration:

Patients should be placed on a standard cholesterol-lowering diet before receiving Hypolip ^® and should continue on this diet during treatment with Hypolip^®. The usual starting dose for all the indications is 10 mg once daily or 5 mg twice. The doses range is 10 to 80 mg once daily. Doses should be individualised according to baseline LDL-C levels, the goal of therapy, and patient response. Adjustment of dosage should be made at intervals of 4 weeks or more. Doses may be given at any time of day with or without food. Children: Treatment experience in a paediatric population with dose of Hypolip ^® up to 80 mg/day is limited. Geriatric (>70 years) use: The safety and efficacy of Hypolip ^® in this population is as similar as < 70 years of age patients with the dose upto 80 mg/day. In patients with Renal Insufficiency: No dosage adjustment is required.

Preparation:

Hypolip ^® 5: Each box contains 10 x 15 tablets in blister pack.
Hypolip ^® 10: Each box contains 10 x 15 tablets in blister pack.
Hypolip ^® 20: Each box contains 30 x 5 tablets in blister pack.